Malik Fady Ibraham, an insider at Cytokinetics Inc (CYTK), purchased 140,752 shares at a price of $10.60 per share on December 15, 2025, totaling $1.49 million. Following this transaction, Ibraham holds 140,752 shares of the company.
Cytokinetics, headquartered in South San Francisco, California, focuses on developing muscle activators and inhibitors for treating diseases that compromise muscle performance. The company has a market capitalization of $7.4 billion and reported a trailing twelve-month EPS of -6.31. Upcoming earnings are scheduled for May 4, 2026, with an estimated EPS of -1.55 and revenue of $27.4 million, followed by another report on August 5, 2026, with an estimated EPS of -1.57 and revenue of $36.7 million.
Insider transactions, such as this purchase, are reported to the SEC and can provide transparency regarding executives' views on the company's stock. However, investors should consider these activities as one of many factors in their decision-making process, examining patterns across multiple insiders and time periods.